The following is a Practice Update interview with Dr Hans Hammers, Associate Professor, Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas. During this interview, Dr Hammers talks about the upcoming combination therapies for the treatment of metastatic renal cell carcinoma (mRCC), such as nivolumab/ipilimumab, axitinib/pembrolizumab, cabozantinib/nivolumab, tivozanib/nivolumab and bevacizumab/atezolizumab combinations currently in development. The clinical trials mentioned during Dr Hammers’s interview were presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference held in San Francisco last week.
Combination therapies for kidney cancer
21 Feb 2018
atezolizumab
Avastin
axitinib
bevacizumab
Cabometyx
cabozantinib
checkpoint inhibitors
combination therapy
immunotherapy
Inlyta
ipilimumab
Keytruda
nivolumab
Opdivo
pembrolizumab
renal cell carcinoma
TKIs
Yervoy
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec